General Information of Disease (ID: DISH2ERD)

Disease Name Cognitive impairment
Synonyms organic mental disorder; cognitive disorder; cognitive disease
Disease Class 6D71: Mild neurocognitive disorder
Definition A disease affects cognitive processes.
Disease Hierarchy
DISKFW6V: Psychiatric disorder
DISH2ERD: Cognitive impairment
ICD Code
ICD-11
ICD-11: 6D71
ICD-10
ICD-10: F06.7
ICD-9
ICD-9: 331.83
Expand ICD-9
331.83
Disease Identifiers
MONDO ID
MONDO_0002039
MESH ID
D003072
UMLS CUI
C0009241
MedGen ID
40371
HPO ID
HP:0100543
SNOMED CT ID
443265004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 5 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Idebenone DMQFDRC Approved Small molecular drug [1]
Levacecarnine hci DMJBOCR Approved Small molecular drug [1]
Mentat DM0AHLX Approved NA [1]
Piracetam DM5BXH9 Approved Small molecular drug [2]
MTHF DMD9Z3V Phase 4 Small molecular drug [3]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 44 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Besipirdine DMLVNTA Phase 3 Small molecular drug [4]
Dabelotine DMP2SGN Phase 3 Small molecular drug [5]
Davunetide DMD7K9X Phase 3 NA [6]
DENBUFYLLINE DM2R15Q Phase 3 Small molecular drug [7]
Eptastigmine DMTV7ZM Phase 3 Small molecular drug [8]
ETHIMIZOL DMEZJFC Phase 3 Small molecular drug [9]
FASORACETAM DM8E51L Phase 3 Small molecular drug [10]
Linopirdine DM0ZOGX Phase 3 Small molecular drug [11]
NA-831 DMJQXFA Phase 3 Small molecular drug [12]
Suronacrine maleate DMH2FN1 Phase 3 Small molecular drug [13]
SUVN-G3031 DM3BO8G Phase 3 NA [14]
LECOZOTAN HYDROCHLORIDE DMBJ4IZ Phase 2/3 Small molecular drug [15]
BIIB104 DMJBDL0 Phase 2a NA [16]
AGB101 DMXDPGC Phase 2 NA [14]
Apaxifylline DMQMV9F Phase 2 Small molecular drug [17]
ASP4345 DMM89G7 Phase 2 NA [18]
AVN 101 DMJFLBC Phase 2 NA [14]
AVN 322 DMK2LGM Phase 2 NA [14]
AVN-101 DMOGFNI Phase 2 Small molecular drug [19]
Basmisanil DMQ8J0U Phase 2 NA [16]
CHF-5074 DMTE071 Phase 2 Small molecular drug [14]
HT-0712 DM2WP8F Phase 2 Small molecular drug [20]
JNJ-39393406 DMUOEKM Phase 2 Small molecular drug [21]
ONO-1603 DMKIZAL Phase 2 Small molecular drug [22]
R-phenserine DM4L5VJ Phase 2 NA [23]
REN-1654 DMTGU6K Phase 2 Small molecular drug [24]
SNK-882 DM254DC Phase 2 Small molecular drug [25]
SR-46559A DMW6UA3 Phase 2 Small molecular drug [26]
T-82 DM4JFMZ Phase 2 Small molecular drug [27]
TN-871 DMH4BFD Phase 2 NA [28]
UCB-11056 DMXLAPF Phase 2 Small molecular drug [29]
V-0191 DMAIFVH Phase 2 NA [30]
HT-2157 DM7C1AJ Phase 1/2 Small molecular drug [31]
ABT-239 DMR7OGL Phase 1 Small molecular drug [32]
ALD-451 DMOPC17 Phase 1 NA [33]
ANAVEX 2-73 DM67OU4 Phase 1 NA [34]
AVL-3288 DMGAKR9 Phase 1 NA [35]
BIMU-1 DMBTSZD Phase 1 Small molecular drug [36]
BNC375 DMI4UY3 Phase 1 NA [14]
Irdabisant DMR3E4L Phase 1 Small molecular drug [37]
PF-06412562 DMLDJGX Phase 1 NA [38]
PF-06669571 DM53RB3 Phase 1 NA [39]
S-17092-1 DMYR1K8 Phase 1 Small molecular drug [40]
Thiopilocarpine DMOLFAU Phase 1 Small molecular drug [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 44 Drug(s)
This Disease is Treated as An Indication in 1 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
Lazabemide DMCULK7 Patented Small molecular drug [42]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 37 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Midafotel DM9FJ7N Discontinued in Phase 3 Small molecular drug [43]
Milameline DMPCY8K Discontinued in Phase 3 Small molecular drug [44]
MOFEGILINE DMJ59A4 Discontinued in Phase 3 Small molecular drug [45]
Org-2766 DMVRA8N Discontinued in Phase 3 Small molecular drug [46]
VELNACRINE DMUB0EC Discontinued in Phase 3 Small molecular drug [47]
ADROGOLIDE HYDROCHLORIDE DMS8JIU Discontinued in Phase 2 Small molecular drug [48]
ALORACETAM DM9YC5Q Discontinued in Phase 2 Small molecular drug [49]
AP-1101 DMOI818 Discontinued in Phase 2 NA [50]
AWD-5239 DMRXYUY Discontinued in Phase 2 NA [51]
BMS-181168 DMGPHTJ Discontinued in Phase 2 Small molecular drug [52]
BY-1949 DM8ZFS3 Discontinued in Phase 2 Small molecular drug [53]
Cebaracetam DMV9400 Discontinued in Phase 2 Small molecular drug [54]
FK-960 DMPD8O2 Discontinued in Phase 2 Small molecular drug [55]
Icopezil maleate DM5WUK9 Discontinued in Phase 2 Small molecular drug [56]
JTP-2942 DM29C6S Discontinued in Phase 2 Small molecular drug [57]
JTP-4819 DMI0UJS Discontinued in Phase 2 Small molecular drug [58]
MCC-257 DMRJ5DB Discontinued in Phase 2 Small molecular drug [59]
PRISOTINOL DMODEGB Discontinued in Phase 2 Small molecular drug [60]
RJR-2403 DMOZEN6 Discontinued in Phase 2 Small molecular drug [61]
S-8510 DM9BEDL Discontinued in Phase 2 Small molecular drug [62]
S-9977 DMEO6A5 Discontinued in Phase 2 Small molecular drug [63]
SGS-111 DM6XJ9D Discontinued in Phase 2 NA [64]
SM-10888 DMBUH7E Discontinued in Phase 2 NA [65]
TAMOLARIZINE HYDROCHLORIDE DM1L5UX Discontinued in Phase 2 Small molecular drug [66]
YM-796 DMDXP3C Discontinued in Phase 2 Small molecular drug [67]
ZIFROSILONE DMC6H4Y Discontinued in Phase 2 Small molecular drug [68]
ABT-560 DMM1LM7 Discontinued in Phase 1 NA [69]
CGP-50068 DM6ZBWB Discontinued in Phase 1 NA [70]
HOE-065 DMNC1A3 Discontinued in Phase 1 Small molecular drug [71]
ITAMELINE DM8139E Discontinued in Phase 1 Small molecular drug [72]
SDZ-210-086 DM8BIV4 Discontinued in Phase 1 NA [73]
SYN-114 DM4JPLM Discontinued in Phase 1 NA [74]
TAZOMELINE DM5PZ60 Discontinued in Phase 1 Small molecular drug [70]
CI-933 DMF94JK Terminated Small molecular drug [77]
Ro-40-1641 DMH80S8 Terminated NA [78]
SEP-227900 DMXRU72 Terminated NA [79]
Thioperamide DM8S593 Terminated Small molecular drug [80]
------------------------------------------------------------------------------------
⏷ Show the Full List of 37 Drug(s)
This Disease is Treated as An Indication in 4 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
(S)-4-(Ethylsulfonyl)benzoylalanine DMEJYV4 Preclinical Small molecular drug [75]
BFF-122 DM6BGJ9 Preclinical Small molecular drug [75]
PF-04859989 DM3U2S5 Preclinical Small molecular drug [75]
PHA-568487 DMM149N Preclinical NA [76]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 17 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AVN-457 DMOAGVC Investigative NA [81]
AVN-458 DM9JGQQ Investigative NA [81]
AVN-492 DMQQC9M Investigative NA [81]
CT-003230 DM3W6PQ Investigative NA [82]
GSK-334429 DM5EO3F Investigative NA [83]
GSK189254A DMKXPOL Investigative Small molecular drug [84]
HT-2678 DMRF73O Investigative NA [85]
IC-041 DMRF5LU Investigative NA [86]
IC-200214 DMLLJH4 Investigative NA [81]
JNJ-1930942 DMKH9O7 Investigative Small molecular drug [87]
LY-392098 DM1KW0L Investigative Small molecular drug [88]
NP-0336 DM906YB Investigative NA [89]
NSD-761 DM9XLWK Investigative NA [81]
PF-4181366 DMC8G4S Investigative Small molecular drug [90]
S-35678 DMMZJTC Investigative NA [81]
S-47445 DMLETMX Investigative NA [81]
UCB-2892 DMQ20A4 Investigative NA [83]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 120 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ACHE TT1RS9F Limited Biomarker [91]
ADCYAP1 TTW4LYC Limited Biomarker [92]
CDK5R1 TTBYM6V Limited Biomarker [93]
CEACAM6 TTIGH2W Limited Biomarker [94]
CHRNA5 TTH2QRX Limited Genetic Variation [95]
COASY TT4YO0Z Limited Biomarker [96]
DBH TTYIP79 Limited Genetic Variation [97]
DYRK1A TTSBVFO Limited Biomarker [98]
EPO TTQG4NR Limited Biomarker [99]
FGF14 TTKJX1V Limited Biomarker [100]
GAD1 TTKGEP3 Limited Altered Expression [101]
GRIA1 TTVPQTF Limited Biomarker [102]
HRH3 TT9JNIC Limited Altered Expression [103]
HTT TTIWZ0O Limited Genetic Variation [104]
LIMK1 TTWL9TY Limited Biomarker [105]
MAOA TT3WG5C Limited Biomarker [106]
MAPT TTS87KH Limited Biomarker [107]
NGFR TTEDJN4 Limited Biomarker [108]
OTC TT5KIO9 Limited Biomarker [109]
PLD2 TTRLMKF Limited Biomarker [110]
PSEN1 TTZ3S8C Limited Biomarker [111]
PSEN2 TTWN3F4 Limited Genetic Variation [112]
SCN1A TTANOZH Limited Genetic Variation [113]
SLC1A1 TTG2A6F Limited Biomarker [114]
SLC1A2 TT2F078 Limited Biomarker [115]
SLC6A8 TTYUHB5 Limited Genetic Variation [116]
TAAR1 TTIU98M Limited Biomarker [117]
TREM2 TTQRMSJ Limited Biomarker [118]
UBE3A TTUZX6V Limited Biomarker [119]
ACAT1 TTK3C21 Disputed Biomarker [120]
CD320 TT0KV32 Disputed Genetic Variation [121]
CHAT TTKYFSB Disputed Biomarker [122]
DRD4 TTE0A2F Disputed Biomarker [123]
HTR1A TTSQIFT Disputed Genetic Variation [124]
HTR2C TTWJBZ5 Disputed Biomarker [125]
MAPK10 TT056SO Disputed Genetic Variation [126]
NRN1 TTS05MJ Disputed Altered Expression [127]
PDE9A TTZOEBC Disputed Biomarker [128]
PEPD TTLZXI0 Disputed Genetic Variation [129]
BACE1 TTJUNZF moderate Biomarker [130]
BCHE TT3MSAO moderate Altered Expression [131]
CHRNA4 TT4H1MQ moderate Biomarker [132]
KCNQ2 TTPXI3S moderate Biomarker [133]
SCN2A TTLJTUF moderate Biomarker [133]
ABCA1 TTJW1GN Strong Biomarker [134]
ABCG1 TTMWDGU Strong Biomarker [135]
ADAM10 TTVXEGU Strong Biomarker [136]
ADRA2A TTWG9A4 Strong Biomarker [137]
ADRB1 TTR6W5O Strong Biomarker [138]
CACNA1C TTZIFHC Strong Biomarker [139]
CASP6 TTKW4ML Strong Biomarker [140]
CDK5 TTL4Q97 Strong Biomarker [141]
CDK9 TT1LVF2 Strong Biomarker [91]
CDKL2 TTMO45N Strong Biomarker [142]
CFP TTLA0VS Strong Genetic Variation [143]
CLCN3 TT8XNZ7 Strong Biomarker [144]
CRTC1 TT4GO0F Strong Altered Expression [145]
CYP2D6 TTVG215 Strong Biomarker [146]
DLG4 TT9PB26 Strong Altered Expression [147]
DRD2 TTEX248 Strong Genetic Variation [148]
DRD3 TT4C8EA Strong Biomarker [149]
FUS TTKGYZ9 Strong Altered Expression [150]
GBA TT1B5PU Strong Genetic Variation [151]
GJB6 TTAU8SJ Strong Biomarker [152]
GRM2 TTXJ47W Strong Genetic Variation [153]
GRM5 TTHS256 Strong Biomarker [154]
GRN TT0LWE3 Strong Biomarker [155]
GSK3B TTRSMW9 Strong Altered Expression [156]
HDAC6 TT5ZKDI Strong Biomarker [157]
HTR2A TTJQOD7 Strong Biomarker [158]
HTR4 TT07C3Y Strong Biomarker [159]
MAOB TTGP7BY Strong Biomarker [160]
MME TT5TKPM Strong Biomarker [161]
MSTN TTM8I2X Strong Altered Expression [162]
NRG1 TTEH395 Strong Altered Expression [163]
PDE10A TTJW4LU Strong Biomarker [164]
PDE2A TTJGW1Z Strong Biomarker [165]
PDE4A TTZ97H5 Strong Biomarker [166]
PREP TTNGKET Strong Biomarker [167]
PTGER3 TTPNGDE Strong Biomarker [168]
PTGS2 TTVKILB Strong Biomarker [169]
SNAP25 TTYQWA0 Strong Biomarker [170]
SNCA TT08OSU Strong Biomarker [171]
SPTBN1 TTS9BDA Strong Biomarker [172]
TDO2 TTXNCBV Strong Biomarker [173]
UBC TTBP3XA Strong Biomarker [174]
VIP TTGTWLF Strong Biomarker [133]
ABCC4 TTUEAFL Definitive Biomarker [175]
AGT TT5C0UB Definitive Biomarker [176]
BRD1 TTT09OB Definitive Genetic Variation [177]
C9orf72 TTA4SHR Definitive Biomarker [178]
CBR1 TTVG0SN Definitive Genetic Variation [179]
CHRNA7 TTLA931 Definitive Genetic Variation [180]
CRBN TTDKGTC Definitive Biomarker [181]
CRH TTA7YIZ Definitive Biomarker [182]
DAO TT7Y3EJ Definitive Altered Expression [183]
EHMT2 TTS6RZT Definitive Biomarker [184]
EPHA4 TTG84D3 Definitive Altered Expression [185]
FABP3 TT3TGLR Definitive Biomarker [186]
FABP5 TTNT2S6 Definitive Biomarker [187]
FDPS TTIKWV4 Definitive Biomarker [188]
FES TTLBY21 Definitive Biomarker [188]
GIP TT40HS5 Definitive Biomarker [189]
GRIA2 TTWM461 Definitive Biomarker [190]
GRPR TTC1MVT Definitive Biomarker [191]
IGF2 TTE8WGO Definitive Therapeutic [192]
KCNJ6 TTTIBVP Definitive Biomarker [193]
MET TTNDSF4 Definitive Biomarker [194]
NR0B2 TT25A9Q Definitive Biomarker [175]
OPHN1 TTU7HRD Definitive Biomarker [195]
OPRL1 TTNT7K8 Definitive Biomarker [196]
OXTR TTSCIUP Definitive Biomarker [197]
PHF8 TT81PFE Definitive Biomarker [198]
PRCP TTTJZ4M Definitive Biomarker [199]
PTGER2 TT1ZAVI Definitive Biomarker [200]
SLC10A2 TTPI1M5 Definitive Biomarker [175]
SLC6A4 TT3ROYC Definitive Biomarker [201]
TMEM97 TT9NXW4 Definitive Biomarker [202]
USP2 TTUEQ1W Definitive Biomarker [203]
WAS TTE8T73 Definitive Biomarker [204]
------------------------------------------------------------------------------------
⏷ Show the Full List of 120 DTT(s)
This Disease Is Related to 5 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC24A2 DTKRWE8 Strong Biomarker [205]
SLC39A13 DTOTKBS Definitive Genetic Variation [206]
SLC4A10 DT7RYVF Definitive Biomarker [207]
SLC51A DTMEQ32 Definitive Biomarker [175]
SLC51B DT1V9AJ Definitive Biomarker [175]
------------------------------------------------------------------------------------
This Disease Is Related to 5 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
AKR1C4 DEAJN47 Limited Biomarker [208]
NMNAT2 DE2HB58 Disputed Altered Expression [209]
XPNPEP1 DE8E6X9 Strong Biomarker [210]
PGPEP1 DEVDR46 Definitive Biomarker [199]
TGM5 DEW8QEH Definitive Biomarker [206]
------------------------------------------------------------------------------------
This Disease Is Related to 157 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AGTPBP1 OTR92JFR Limited Biomarker [211]
AMPH OTWPGWZX Limited Biomarker [212]
AP3B2 OT7BFBLP Limited Biomarker [213]
ARHGEF7 OT9BPJCL Limited Biomarker [214]
ASCC1 OTH4VAP9 Limited Biomarker [214]
CALB1 OTM7IXDG Limited Altered Expression [215]
CALB2 OTSNMCG9 Limited Biomarker [216]
CALHM1 OTUZPEYQ Limited Biomarker [217]
CEACAM4 OT0C7YUD Limited Biomarker [94]
CHL1 OT6E6E8P Limited Altered Expression [218]
CLIP2 OTSCIQIY Limited Genetic Variation [219]
CUX1 OTU1LCNJ Limited Biomarker [220]
DAB1 OTPL9MA3 Limited Biomarker [221]
DBN1 OTZVKG8A Limited Biomarker [222]
DISC1 OT43AW4H Limited Altered Expression [223]
DNAAF3 OT3OHO0O Limited Altered Expression [224]
EIF2S1 OTM0GDTP Limited Posttranslational Modification [225]
FMR1 OTWEV0T5 Limited Biomarker [226]
GTF2IRD1 OTEG9KU1 Limited Biomarker [227]
GZMH OTG3259L Limited Biomarker [228]
HDGFL3 OTNN7WYH Limited Biomarker [213]
HOMER2 OT4JGKJF Limited Biomarker [213]
HOXA1 OTMSOJ7D Limited Genetic Variation [229]
LGI1 OTPS77HO Limited Biomarker [230]
MAPK8IP2 OTDUHLN0 Limited Genetic Variation [231]
NOVA2 OTQ2X3Q4 Limited Altered Expression [232]
NPAS4 OTA3HH6W Limited Altered Expression [233]
NRG3 OTIFZ5CT Limited Genetic Variation [234]
NTS OTPGDNQS Limited Altered Expression [235]
NUBP1 OTE8RAKZ Limited Biomarker [96]
OMA1 OT0JRVY7 Limited Altered Expression [224]
PAK3 OT80M3BV Limited Biomarker [236]
PLB1 OTZ6TTYV Limited Biomarker [237]
REST OTLL92LQ Limited Genetic Variation [238]
RUNX1T1 OT30DED5 Limited Biomarker [208]
SYNJ1 OTTE02XC Limited Altered Expression [239]
SYNM OTOI8TRJ Limited Biomarker [240]
TM7SF2 OTILU5S7 Limited Biomarker [241]
TPM2 OTA1L0P8 Limited Biomarker [242]
ADNP OTEGICWR Disputed Biomarker [243]
AGFG1 OTI8ZKC4 Disputed Biomarker [244]
DCLRE1C OTW3KB1I Disputed Biomarker [245]
DIPK2A OTL1DBIM Disputed Biomarker [246]
GCHFR OTEOT8GI Disputed Biomarker [93]
GTF2I OTUYL1TQ Disputed Biomarker [227]
HCFC1 OT0UCK62 Disputed Genetic Variation [247]
HCLS1 OTX7WGYN Disputed Biomarker [220]
MED13L OTSP1W0F Disputed Genetic Variation [247]
OR2AG1 OTEITRP4 Disputed Biomarker [248]
SIGLEC7 OTNDLURR Disputed Biomarker [220]
SRPX2 OT6A63TX Disputed Genetic Variation [247]
TCN2 OT41D0L3 Disputed Biomarker [121]
TRAPPC9 OTF0CVMC Disputed Genetic Variation [249]
AFF2 OTMF1PZW moderate Biomarker [133]
CAPRIN1 OTEJAMS3 moderate Biomarker [133]
NRXN1 OTJN1JQA moderate Biomarker [133]
AFF4 OTTL5Y8R Strong Biomarker [250]
ANK3 OTJ3IRBP Strong Genetic Variation [251]
ASL OTI2NGQR Strong Genetic Variation [252]
BAIAP2 OT1KKMYZ Strong Biomarker [253]
CAMK4 OT47RDGV Strong Genetic Variation [205]
CC2D1A OTVPU04K Strong Biomarker [254]
CCDC141 OTQ9HA3I Strong Biomarker [255]
CCDC91 OTLZNXDL Strong Biomarker [142]
CHRDL1 OTGMWVVA Strong Biomarker [256]
CIP2A OTVS2GXA Strong Biomarker [257]
DEGS2 OTXC27FL Strong Genetic Variation [258]
DTNBP1 OT9UQT2S Strong Genetic Variation [259]
EPM2A OTJU4IAG Strong Genetic Variation [260]
FRRS1L OT24ABVC Strong Genetic Variation [261]
GADD45G OT8V1J4M Strong Biomarker [262]
GEN1 OT1XFQXF Strong Biomarker [263]
GOLGA6A OTHU9MRX Strong Biomarker [264]
HARS1 OTHOEOTS Strong Genetic Variation [265]
IFIT1 OTXOQDSG Strong Biomarker [142]
KL OTD4VWU6 Strong Altered Expression [266]
KLHDC8B OTKP6LCR Strong Biomarker [256]
LRP8 OTZ71YV2 Strong Altered Expression [267]
LYNX1 OTK4103B Strong Biomarker [268]
NCK2 OTUYPF55 Strong Biomarker [269]
NCS1 OT6JHAWM Strong Biomarker [270]
NPS OTEG25A2 Strong Biomarker [271]
NRGN OTVGE10W Strong Altered Expression [272]
NSUN5 OTBN7RS8 Strong Biomarker [273]
NUFIP2 OTZBZ224 Strong Biomarker [226]
OLIG2 OTMCN6D3 Strong Biomarker [274]
PCDH10 OT2GIT0E Strong Genetic Variation [275]
PCDH19 OTSOW3MV Strong Genetic Variation [275]
PLEKHF1 OT9OL16U Strong Biomarker [276]
PSMC1 OTLHD56E Strong Biomarker [142]
PSME3 OTSTC4YY Strong Altered Expression [277]
PVALB OTZW1WVQ Strong Biomarker [233]
RCBTB1 OTAYELI8 Strong Biomarker [264]
RELN OTLKMW1O Strong Altered Expression [278]
RPS27A OTIIGGZ2 Strong Biomarker [174]
RTL1 OTOT33IM Strong Biomarker [210]
SEMA5A OTUOIOJV Strong Biomarker [150]
SETD1A OTVVWRIC Strong Altered Expression [279]
SETMAR OTE2MIMZ Strong Biomarker [210]
SFTPA1 OT87XL1U Strong Biomarker [280]
SMPD3 OTHQBETH Strong Biomarker [281]
SRCIN1 OTQZNQQ5 Strong Biomarker [282]
SRSF11 OTZSV6CZ Strong Altered Expression [267]
SUCLA2 OTMZD4PW Strong Biomarker [283]
SYP OTFJKMO4 Strong Altered Expression [147]
TMEM106B OTUWA6NW Strong Genetic Variation [284]
TNFAIP8L2 OTII0RM0 Strong Biomarker [285]
TSPAN31 OT8WQ83R Strong Biomarker [286]
ANP32A OTRHPFO2 Definitive Genetic Variation [287]
ARC OTN2QQPG Definitive Biomarker [288]
ARSD OTAHW9M8 Definitive Biomarker [289]
ASTN2 OTF0W2FJ Definitive Biomarker [290]
ATP1A3 OTM8EG6H Definitive Genetic Variation [291]
ATP5F1A OT3FZDLX Definitive Biomarker [292]
AUTS2 OTAEXHSC Definitive Biomarker [293]
CINP OTZ31XOT Definitive Genetic Variation [294]
CORT OTX3GUHB Definitive Altered Expression [295]
CTRL OTB6NA5O Definitive Genetic Variation [296]
EIF2S2 OTXF0B09 Definitive Posttranslational Modification [225]
EIF2S3 OTARRES9 Definitive Posttranslational Modification [225]
FAM107A OTBG61YZ Definitive Altered Expression [297]
FAM3B OTC2S91N Definitive Genetic Variation [179]
FOSB OTW6C05J Definitive Biomarker [298]
FPGT-TNNI3K OTJ6CWUN Definitive Biomarker [299]
FUT1 OTODG57A Definitive Genetic Variation [296]
HES5 OTW7JEHV Definitive Altered Expression [300]
HOOK1 OTTTKV7V Definitive Biomarker [301]
HSPB6 OTFPLGZI Definitive Altered Expression [302]
IL1RAPL1 OTW3T4B2 Definitive Biomarker [303]
IRF2BP2 OTSSRRCA Definitive Biomarker [304]
KIDINS220 OTLBH2MA Definitive Biomarker [206]
LAMB2 OT71OI2Y Definitive Biomarker [305]
MCIDAS OTK1JVAH Definitive Biomarker [306]
NCOA1 OTLIUJQD Definitive Biomarker [307]
NECTIN3 OTS8N7MK Definitive Biomarker [308]
NEUROD1 OTZQ7QJ2 Definitive Biomarker [309]
NGB OTW0SIUY Definitive Biomarker [310]
NMB OT4NLN6H Definitive Biomarker [191]
NOL3 OT1K0L0D Definitive Biomarker [196]
OPN1MW OTPJ7LX4 Definitive Biomarker [204]
ORM1 OTZKSBRE Definitive Biomarker [292]
PNOC OTJEAADN Definitive Biomarker [196]
PSMG1 OTZ5I6UM Definitive Biomarker [92]
PTPN5 OT2H1KDK Definitive Genetic Variation [311]
PTPRG OT9N2WOF Definitive Biomarker [206]
RAB40AL OTZWO8A5 Definitive Biomarker [312]
RBM3 OTAJ7R31 Definitive Altered Expression [313]
RTN3 OTGZ51QF Definitive Altered Expression [313]
SETD4 OTBMCZQA Definitive Biomarker [179]
SHROOM4 OT33GO6E Definitive Biomarker [314]
SMAD4 OTWQWCKG Definitive Biomarker [315]
SPAG11A OTNQ9UB0 Definitive Biomarker [200]
SPG11 OTZ7LJX4 Definitive Biomarker [316]
SYNGAP1 OT41HVYQ Definitive Altered Expression [317]
TJP1 OTBDCUPK Definitive Altered Expression [318]
TPSG1 OTDESHKT Definitive Biomarker [319]
TSC1 OTFF4YZ7 Definitive Biomarker [320]
------------------------------------------------------------------------------------
⏷ Show the Full List of 157 DOT(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4288).
3 ClinicalTrials.gov (NCT00955955) Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of UroGene.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002175)
6 Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
7 Denbufylline in dementia: a double-blind controlled study. Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):505-10.
8 Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86.
9 Pharmacokinetics of ethimizol in man. Pharmazie. 1985 Jun;40(6):410-1.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003134)
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2599).
12 ClinicalTrials.gov (NCT03538522) A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831. U.S. National Institutes of Health.
13 Handbook of Dementing Illnesses, Morris John. Page(570).
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 ClinicalTrials.gov (NCT00277810) Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease. U.S. National Institutes of Health.
16 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
17 Xanthines as Adenosine Receptor Antagonists. Handb Exp Pharmacol. 2011; (200): 10.1007/978-3-642-13443-2_6.
18 ClinicalTrials.gov (NCT03557931) A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication. U.S. National Institutes of Health.
19 Clinical pipeline report, company report or official report of Avineuro.
20 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018324)
21 ClinicalTrials.gov (NCT01556217) A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers. U.S. National Institutes of Health.
22 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002119)
23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021506)
24 ClinicalTrials.gov (NCT00107055) Study of REN-1654 in Patients With Sciatica Pain. U.S. National Institutes of Health.
25 Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des. 2002;8(2):125-38.
26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001599)
27 Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):97-103.
28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001383)
29 Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
30 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029128)
31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6126).
32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1218).
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036478)
34 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
35 ClinicalTrials.gov (NCT01851603) Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects. U.S. National Institutes of Health.
36 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 234).
37 ClinicalTrials.gov (NCT01903824) Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects. U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT02418819) A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Schizophrenic Patients. U.S. National Institutes of Health.
39 ClinicalTrials.gov (NCT02565628) PF-06669571 In Subjects With Idiopathic Parkinson's Disease.
40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011104)
41 SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices. Eur J Pharmacol. 1992 Nov 3;222(1):21-5.
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6640).
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002722)
44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 301).
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002656)
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000019)
47 Velnacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2004;(2):CD004748.
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006590)
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001404)
50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035006)
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001326)
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001318)
53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001319)
54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001741)
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008887)
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006556)
57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002435)
58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006163)
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015003)
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000145)
61 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3994).
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005238)
63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001724)
64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017512)
65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001320)
66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000299)
67 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 287).
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001855)
69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026773)
70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006554)
71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006815)
72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004062)
73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001734)
74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025583)
75 Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018656)
77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001409)
78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003424)
79 The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors. Open Med Chem J. 2010; 4: 3-9.
80 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1267).
81 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
82 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
83 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
84 The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
85 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
86 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1295).
87 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3966).
88 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4251).
89 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471).
90 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1309).
91 TAK-071, a novel M(1) positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.Neuropsychopharmacology. 2019 Apr;44(5):950-960. doi: 10.1038/s41386-018-0168-8. Epub 2018 Aug 1.
92 Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.Mol Neurobiol. 2018 Nov;55(11):8263-8277. doi: 10.1007/s12035-018-0972-5. Epub 2018 Mar 10.
93 The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit in the transgenic mice.Neuropsychopharmacology. 2011 Aug;36(9):1848-58. doi: 10.1038/npp.2011.69. Epub 2011 May 4.
94 Visual encoding, consolidation, and retrieval in amyotrophic lateral sclerosis: executive function as a mediator, and predictor of performance.Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):193-201. doi: 10.1080/21678421.2016.1272615. Epub 2017 Jan 13.
95 Relationship of common variants in CHRNA5 with early-onset schizophrenia and executive function.Schizophr Res. 2019 Apr;206:407-412. doi: 10.1016/j.schres.2018.10.011. Epub 2018 Oct 23.
96 L-3-n-Butylphthalide Regulates Proliferation, Migration, and Differentiation of Neural Stem Cell In Vitro and Promotes Neurogenesis in APP/PS1 Mouse Model by Regulating BDNF/TrkB/CREB/Akt Pathway.Neurotox Res. 2018 Oct;34(3):477-488. doi: 10.1007/s12640-018-9905-3. Epub 2018 May 4.
97 Associations between the DBH gene, plasma dopamine -hydroxylase activity and cognitive measures in Han Chinese patients with schizophrenia.Schizophr Res. 2018 Mar;193:58-63. doi: 10.1016/j.schres.2017.06.028. Epub 2017 Jun 21.
98 Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.Dis Model Mech. 2018 Sep 27;11(9):dmm035634. doi: 10.1242/dmm.035634.
99 Erythropoietin Reduces Neurodegeneration and Long-Term Memory Deficits Following Sevoflurane Exposure in Neonatal Rats.Neurotox Res. 2019 Nov;36(4):817-826. doi: 10.1007/s12640-019-00028-8. Epub 2019 Apr 5.
100 Parallel fiber to Purkinje cell synaptic impairment in a mouse model of spinocerebellar ataxia type 27.Front Cell Neurosci. 2015 Jun 4;9:205. doi: 10.3389/fncel.2015.00205. eCollection 2015.
101 Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features.Am J Psychiatry. 2011 Sep;168(9):921-9. doi: 10.1176/appi.ajp.2011.11010052. Epub 2011 Jun 1.
102 Loss of thin spines and small synapses contributes to defective hippocampal function in aged mice.Neurobiol Aging. 2018 Nov;71:91-104. doi: 10.1016/j.neurobiolaging.2018.07.010. Epub 2018 Jul 24.
103 Histamine, histamine H(3) receptor, and alcohol use disorder.Br J Pharmacol. 2020 Feb;177(3):634-641. doi: 10.1111/bph.14634. Epub 2019 Apr 10.
104 Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington's disease patients.Metab Brain Dis. 2019 Jun;34(3):715-720. doi: 10.1007/s11011-019-00405-4. Epub 2019 Mar 9.
105 In-depth analysis of spatial cognition in Williams syndrome: A critical assessment of the role of the LIMK1 gene.Neuropsychologia. 2006;44(5):679-85. doi: 10.1016/j.neuropsychologia.2005.08.007. Epub 2005 Oct 10.
106 Prenatal iron deficiency and monoamine oxidase A (MAOA) polymorphisms: combined risk for later cognitive performance in rhesus monkeys.Genes Nutr. 2014 Mar;9(2):381. doi: 10.1007/s12263-013-0381-3. Epub 2014 Jan 9.
107 Functional Connectivity between Hippocampus and Lateral Septum is Affected in Very Young Alzheimer's Transgenic Mouse Model.Neuroscience. 2019 Mar 1;401:96-105. doi: 10.1016/j.neuroscience.2018.12.042. Epub 2018 Dec 30.
108 Intramuscular delivery of p75NTR ectodomain by an AAV vector attenuates cognitive deficits and Alzheimer's disease-like pathologies in APP/PS1 transgenic mice.J Neurochem. 2016 Jul;138(1):163-73. doi: 10.1111/jnc.13616. Epub 2016 Jun 6.
109 Long-term treatment of girls with ornithine transcarbamylase deficiency.N Engl J Med. 1996 Sep 19;335(12):855-9. doi: 10.1056/NEJM199609193351204.
110 Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits.J Neurosci. 2010 Dec 8;30(49):16419-28. doi: 10.1523/JNEUROSCI.3317-10.2010.
111 Deuterated polyunsaturated fatty acids reduce brain lipid peroxidation and hippocampal amyloid -peptide levels, without discernable behavioral effects in an APP/PS1 mutant transgenic mouse model of Alzheimer's disease.Neurobiol Aging. 2018 Jun;66:165-176. doi: 10.1016/j.neurobiolaging.2018.02.024. Epub 2018 Mar 5.
112 Cognitive deficits in familial Alzheimer's disease associated with M239V mutation of presenilin 2.Dement Geriatr Cogn Disord. 2006;22(3):238-43. doi: 10.1159/000094972. Epub 2006 Aug 10.
113 A human Dravet syndrome model from patient induced pluripotent stem cells.Mol Brain. 2013 May 2;6:19. doi: 10.1186/1756-6606-6-19.
114 EAAC1 gene deletion alters zinc homeostasis and enhances cortical neuronal injury after transient cerebral ischemia in mice.J Trace Elem Med Biol. 2012 Jun;26(2-3):85-8. doi: 10.1016/j.jtemb.2012.04.010. Epub 2012 May 8.
115 Ceftriaxone Improves Cognitive Function and Upregulates GLT-1-Related Glutamate-Glutamine Cycle in APP/PS1 Mice.J Alzheimers Dis. 2018;66(4):1731-1743. doi: 10.3233/JAD-180708.
116 Deletion of the creatine transporter gene in neonatal, but not adult, mice leads to cognitive deficits.J Inherit Metab Dis. 2019 Sep;42(5):966-974. doi: 10.1002/jimd.12137. Epub 2019 Jul 4.
117 Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.Neurotoxicology. 2017 Dec;63:57-69. doi: 10.1016/j.neuro.2017.09.006. Epub 2017 Sep 15.
118 Upregulation of TREM2 Ameliorates Neuroinflammatory Responses and Improves Cognitive Deficits Triggered by Surgical Trauma in Appswe/PS1dE9 Mice.Cell Physiol Biochem. 2018;46(4):1398-1411. doi: 10.1159/000489155. Epub 2018 Apr 18.
119 Activity-Dependent Arc Expression and Homeostatic Synaptic Plasticity Are Altered in Neurons from a Mouse Model of Angelman Syndrome.Front Mol Neurosci. 2017 Jul 28;10:234. doi: 10.3389/fnmol.2017.00234. eCollection 2017.
120 ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD.Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3081-6. doi: 10.1073/pnas.0913828107. Epub 2010 Jan 26.
121 B vitamin polymorphisms and behavior: evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline.Neurosci Biobehav Rev. 2014 Nov;47:307-20. doi: 10.1016/j.neubiorev.2014.08.006. Epub 2014 Aug 27.
122 Impairment of spatial learning and memory in transgenic mice overexpressing human fibroblast growth factor-23.Brain Res. 2011 Sep 15;1412:9-17. doi: 10.1016/j.brainres.2011.07.028. Epub 2011 Jul 26.
123 DRD2 and DRD4 genes related to cognitive deficits in HIV-infected adults who abuse alcohol.Behav Brain Funct. 2015 Aug 27;11:25. doi: 10.1186/s12993-015-0072-x.
124 The effect of serotonin 1A receptor polymorphism on the cognitive function of premenstrual dysphoric disorder.Eur Arch Psychiatry Clin Neurosci. 2014 Dec;264(8):729-39. doi: 10.1007/s00406-013-0466-4. Epub 2013 Oct 26.
125 Stimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation.Neuropsychopharmacology. 2014 Apr;39(5):1125-34. doi: 10.1038/npp.2013.313. Epub 2013 Nov 7.
126 Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.Hum Genet. 2013 Apr;132(4):461-71. doi: 10.1007/s00439-012-1260-5. Epub 2013 Jan 18.
127 Impact of Neuritin 1 (NRN1) polymorphisms on fluid intelligence in schizophrenia.Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):428-437. doi: 10.1002/ajmg.b.30996.
128 Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.J Med Chem. 2012 Nov 8;55(21):9045-54. doi: 10.1021/jm3007799. Epub 2012 Jul 25.
129 Genome-wide association study of schizophrenia in Ashkenazi Jews.Am J Med Genet B Neuropsychiatr Genet. 2015 Dec;168(8):649-59. doi: 10.1002/ajmg.b.32349. Epub 2015 Jul 21.
130 In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease.Nat Neurosci. 2019 Apr;22(4):524-528. doi: 10.1038/s41593-019-0352-0. Epub 2019 Mar 11.
131 Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.Behav Brain Res. 2019 Jan 1;356:18-40. doi: 10.1016/j.bbr.2018.08.010. Epub 2018 Aug 14.
132 Pharmacological characterization of JWX-A0108 as a novel type I positive allosteric modulator of 7 nAChR that can reverse acoustic gating deficits in a mouse prepulse inhibition model.Acta Pharmacol Sin. 2019 Jun;40(6):737-745. doi: 10.1038/s41401-018-0163-y. Epub 2018 Oct 17.
133 Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing.Am J Hum Genet. 2013 Aug 8;93(2):249-63. doi: 10.1016/j.ajhg.2013.06.012. Epub 2013 Jul 11.
134 Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice.PLoS One. 2017 Feb 27;12(2):e0172161. doi: 10.1371/journal.pone.0172161. eCollection 2017.
135 Retinoid X Receptor Alpha Nitro-ligand Z-10 and Its Optimized Derivative Z-36 Reduce -Amyloid Plaques in Alzheimer's Disease Mouse Model.Mol Pharm. 2019 Feb 4;16(2):480-488. doi: 10.1021/acs.molpharmaceut.8b00096. Epub 2018 Dec 31.
136 Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.J Clin Invest. 2019 May 6;129(6):2390-2403. doi: 10.1172/JCI120616. eCollection 2019 May 6.
137 (2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction.Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17296-301. doi: 10.1073/pnas.1409513111. Epub 2014 Nov 17.
138 Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders.PLoS One. 2017 Jul 26;12(7):e0180319. doi: 10.1371/journal.pone.0180319. eCollection 2017.
139 Sex-specific effects of Cacna1c haploinsufficiency on object recognition, spatial memory, and reversal learning capabilities in rats.Neurobiol Learn Mem. 2018 Nov;155:543-555. doi: 10.1016/j.nlm.2018.05.012. Epub 2018 May 23.
140 Methylene blue inhibits Caspase-6 activity, and reverses Caspase-6-induced cognitive impairment and neuroinflammation in aged mice.Acta Neuropathol Commun. 2019 Dec 16;7(1):210. doi: 10.1186/s40478-019-0856-6.
141 Inhibition of cyclin-dependent kinase 5 activity alleviates diabetes-related cognitive deficits.FASEB J. 2019 Dec;33(12):14506-14515. doi: 10.1096/fj.201901292R. Epub 2019 Nov 5.
142 Key role of soluble epoxide hydrolase in the neurodevelopmental disorders of offspring after maternal immune activation.Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7083-7088. doi: 10.1073/pnas.1819234116. Epub 2019 Mar 19.
143 Comparison of prefrontal hemodynamic responses and cognitive deficits between adult patients with autism spectrum disorder and schizophrenia.Schizophr Res. 2019 Apr;206:420-427. doi: 10.1016/j.schres.2018.10.007. Epub 2018 Oct 11.
144 TGF-beta/TGF-beta RII/CLC-3 axis promotes cognitive disorders in diabetes.Front Biosci (Landmark Ed). 2019 Jan 1;24(3):482-493. doi: 10.2741/4730.
145 Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease.Cereb Cortex. 2017 Feb 1;27(2):1501-1511. doi: 10.1093/cercor/bhv332.
146 Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.J Int Neuropsychol Soc. 2010 Sep;16(5):890-901. doi: 10.1017/S1355617710000779. Epub 2010 Aug 23.
147 Developmental neurotoxicity in the context of multiple sevoflurane exposures: Potential role of histone deacetylase 6.Neurotoxicol Teratol. 2019 Jul-Aug;74:106813. doi: 10.1016/j.ntt.2019.106813. Epub 2019 Jun 26.
148 Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease.Acta Neurol Scand. 2018 Jan;137(1):91-98. doi: 10.1111/ane.12812. Epub 2017 Sep 4.
149 Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats.Psychopharmacology (Berl). 2005 May;179(3):567-75. doi: 10.1007/s00213-004-2096-z. Epub 2004 Dec 24.
150 FUS-mediated dysregulation of Sema5a, an autism-related gene, in FUS mice with hippocampus-dependent cognitive deficits.Hum Mol Genet. 2019 Nov 15;28(22):3777-3791. doi: 10.1093/hmg/ddz217.
151 Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.Mov Disord. 2019 Dec;34(12):1839-1850. doi: 10.1002/mds.27845. Epub 2019 Sep 10.
152 Drebrins and Connexins: A Biomedical Perspective.Adv Exp Med Biol. 2017;1006:225-247. doi: 10.1007/978-4-431-56550-5_13.
153 mGluR2 versus mGluR3 Metabotropic Glutamate Receptors in Primate Dorsolateral Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Working Memory Networks.Cereb Cortex. 2018 Mar 1;28(3):974-987. doi: 10.1093/cercor/bhx005.
154 Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia.Brain Imaging Behav. 2018 Apr;12(2):509-517. doi: 10.1007/s11682-017-9712-0.
155 Elevated progranulin contributes to synaptic and learning deficit due to loss of fragile X mental retardation protein.Brain. 2017 Dec 1;140(12):3215-3232. doi: 10.1093/brain/awx265.
156 Ginsenoside compound K attenuates cognitive deficits in vascular dementia rats by reducing the A deposition.J Pharmacol Sci. 2019 Mar;139(3):223-230. doi: 10.1016/j.jphs.2019.01.013. Epub 2019 Feb 13.
157 Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.Neurochem Res. 2019 Nov;44(11):2460-2469. doi: 10.1007/s11064-019-02882-6. Epub 2019 Sep 30.
158 Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.J Clin Psychiatry. 2018 May/Jun;79(3):17m11753. doi: 10.4088/JCP.17m11753.
159 A role for 5-HT(4) receptors in human learning and memory.Psychol Med. 2020 Dec;50(16):2722-2730. doi: 10.1017/S0033291719002836. Epub 2019 Oct 16.
160 Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.Sci Adv. 2019 Mar 20;5(3):eaav0316. doi: 10.1126/sciadv.aav0316. eCollection 2019 Mar.
161 Regulation of Neprilysin Activity and Cognitive Functions in Rats After Prenatal Hypoxia.Neurochem Res. 2019 Jun;44(6):1387-1398. doi: 10.1007/s11064-019-02796-3. Epub 2019 Apr 20.
162 Myostatin Is Associated With Cognitive Decline in an Animal Model of Alzheimer's Disease.Mol Neurobiol. 2019 Mar;56(3):1984-1991. doi: 10.1007/s12035-018-1201-y. Epub 2018 Jul 7.
163 Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III.Behav Brain Res. 2018 Nov 1;353:227-235. doi: 10.1016/j.bbr.2018.03.026. Epub 2018 Mar 17.
164 Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.Curr Drug Targets. 2019;20(1):122-143. doi: 10.2174/1389450119666180808105056.
165 Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.Chem Pharm Bull (Tokyo). 2017;65(11):1058-1077. doi: 10.1248/cpb.c17-00564.
166 Inhibition of Phosphodiesterase-4 Reverses A-Induced Memory Impairment by Regulation of HPA Axis Related cAMP Signaling.Front Aging Neurosci. 2018 Jul 24;10:204. doi: 10.3389/fnagi.2018.00204. eCollection 2018.
167 Subcellular Localization of Prolyl Endopeptidase During the First Wave of Rat Spermatogenesis and in Rat and Human Sperm.J Histochem Cytochem. 2019 Apr;67(4):229-243. doi: 10.1369/0022155418810064. Epub 2018 Oct 31.
168 PGE(2)-EP3 signaling pathway impairs hippocampal presynaptic long-term plasticity in a mouse model of Alzheimer's disease.Neurobiol Aging. 2017 Feb;50:13-24. doi: 10.1016/j.neurobiolaging.2016.10.012. Epub 2016 Oct 17.
169 Distinct influence of COX-1 and COX-2 on neuroinflammatory response and associated cognitive deficits during high altitude hypoxia.Neuropharmacology. 2019 Mar 1;146:138-148. doi: 10.1016/j.neuropharm.2018.11.026. Epub 2018 Nov 23.
170 Cell-Specific Loss of SNAP25 from Cortical Projection Neurons Allows Normal Development but Causes Subsequent Neurodegeneration.Cereb Cortex. 2019 May 1;29(5):2148-2159. doi: 10.1093/cercor/bhy127.
171 Parkinson's disease-related non-motor features as risk factors for post-operative delirium in spinal surgery.PLoS One. 2018 Apr 9;13(4):e0195749. doi: 10.1371/journal.pone.0195749. eCollection 2018.
172 RKIP-Mediated NF-B Signaling is involved in ELF-MF-mediated improvement in AD rat.Int J Med Sci. 2018 Nov 5;15(14):1658-1666. doi: 10.7150/ijms.28411. eCollection 2018.
173 Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation. Acta Neuropsychiatr. 2020 Feb;32(1):43-53.
174 Correlation of ubiquitin C terminal hydrolase and S100 with cognitive deficits in young adults with mild traumatic brain injury.Neurol India. 2017 Jul-Aug;65(4):761-766. doi: 10.4103/neuroindia.NI_884_15.
175 Diabetic cognitive dysfunction is associated with increased bile acids in liver and activation of bile acid signaling in intestine.Toxicol Lett. 2018 May 1;287:10-22. doi: 10.1016/j.toxlet.2018.01.006. Epub 2018 Jan 31.
176 Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.FEBS Lett. 2012 Oct 19;586(20):3737-45. doi: 10.1016/j.febslet.2012.09.004. Epub 2012 Sep 13.
177 Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia.Neurobiol Learn Mem. 2017 May;141:44-52. doi: 10.1016/j.nlm.2017.03.009. Epub 2017 Mar 21.
178 Phenotypic variability and neuropsychological findings associated with C9orf72 repeat expansions in a Bulgarian dementia cohort.PLoS One. 2018 Dec 14;13(12):e0208383. doi: 10.1371/journal.pone.0208383. eCollection 2018.
179 Genetic dissection of the Down syndrome critical region.Hum Mol Genet. 2015 Nov 15;24(22):6540-51. doi: 10.1093/hmg/ddv364. Epub 2015 Sep 15.
180 The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.Neuropharmacology. 2015 Sep;96(Pt B):274-88. doi: 10.1016/j.neuropharm.2015.02.006. Epub 2015 Feb 19.
181 A missense mutation in the CRBN gene that segregates with intellectual disability and self-mutilating behaviour in a consanguineous Saudi family.J Med Genet. 2017 Apr;54(4):236-240. doi: 10.1136/jmedgenet-2016-104117. Epub 2017 Jan 31.
182 Heart rate dynamics and behavioral responses during acute emotional challenge in corticotropin-releasing factor receptor 1-deficient and corticotropin-releasing factor-overexpressing mice.Neuroscience. 2005;134(4):1113-22. doi: 10.1016/j.neuroscience.2005.05.027.
183 Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging.Sci Rep. 2017 Nov 1;7(1):14849. doi: 10.1038/s41598-017-13951-7.
184 Increased H3K9 methylation and impaired expression of Protocadherins are associated with the cognitive dysfunctions of the Kleefstra syndrome.Nucleic Acids Res. 2018 Jun 1;46(10):4950-4965. doi: 10.1093/nar/gky196.
185 Amyloid- oligomers synaptotoxicity: The emerging role of EphA4/c-Abl signaling in Alzheimer's disease.Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt A):1148-1159. doi: 10.1016/j.bbadis.2018.01.023. Epub 2018 Jan 31.
186 Ramelteon Improves Post-traumatic Stress Disorder-Like Behaviors Exhibited by Fatty Acid-Binding Protein 3 Null Mice.Mol Neurobiol. 2018 Apr;55(4):3577-3591. doi: 10.1007/s12035-017-0587-2. Epub 2017 May 17.
187 Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets.J Neurochem. 2018 Jan;144(1):81-92. doi: 10.1111/jnc.14249.
188 Targeted inhibition of RAGE reduces amyloid- influx across the blood-brain barrier and improves cognitive deficits in db/db mice.Neuropharmacology. 2018 Mar 15;131:143-153. doi: 10.1016/j.neuropharm.2017.12.026. Epub 2017 Dec 14.
189 A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.Hippocampus. 2018 May;28(5):358-372. doi: 10.1002/hipo.22837. Epub 2018 Mar 5.
190 Neonatal exposure to sevoflurane caused cognitive deficits by dysregulating SK2 channels and GluA2-lacking AMPA receptors in juvenile rat hippocampus.Neuropharmacology. 2018 Oct;141:66-75. doi: 10.1016/j.neuropharm.2018.08.014. Epub 2018 Aug 22.
191 Gastrin-releasing peptide facilitates glutamatergic transmission in the hippocampus and effectively prevents vascular dementia induced cognitive and synaptic plasticity deficits.Exp Neurol. 2017 Jan;287(Pt 1):75-83. doi: 10.1016/j.expneurol.2016.08.008. Epub 2016 Aug 15.
192 A critical role for IGF-II in memory consolidation and enhancement.Nature. 2011 Jan 27;469(7331):491-7. doi: 10.1038/nature09667.
193 Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.Neurobiol Dis. 2017 Jul;103:1-10. doi: 10.1016/j.nbd.2017.03.009. Epub 2017 Mar 22.
194 Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability.Am J Psychiatry. 2010 Apr;167(4):436-43. doi: 10.1176/appi.ajp.2009.09050615. Epub 2010 Jan 15.
195 Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligophrenin-1 mouse model of intellectual disability.Hum Mol Genet. 2016 Jun 1;25(11):2314-2323. doi: 10.1093/hmg/ddw102. Epub 2016 May 4.
196 Intra-nasal dopamine alleviates cognitive deficits in tgDISC1 rats which overexpress the human DISC1 gene.Neurobiol Learn Mem. 2017 Dec;146:12-20. doi: 10.1016/j.nlm.2017.10.015. Epub 2017 Oct 28.
197 Evidence that genetic variation in the oxytocin receptor (OXTR) gene influences social cognition in ADHD.Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):697-702. doi: 10.1016/j.pnpbp.2010.03.029. Epub 2010 Mar 27.
198 Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway.Nat Commun. 2018 Jan 9;9(1):114. doi: 10.1038/s41467-017-02531-y.
199 Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rat.Neuropharmacology. 2017 Jun;119:15-25. doi: 10.1016/j.neuropharm.2017.03.024. Epub 2017 Mar 22.
200 Impaired lipid metabolism markers to assess the risk of neuroinflammation in autism spectrum disorder.Metab Brain Dis. 2018 Aug;33(4):1141-1153. doi: 10.1007/s11011-018-0206-6. Epub 2018 Mar 22.
201 5-HTTLPR and early childhood adversities moderate cognitive and emotional processing in adolescence.PLoS One. 2012;7(11):e48482. doi: 10.1371/journal.pone.0048482. Epub 2012 Nov 28.
202 Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease.J Neurochem. 2017 Feb;140(4):561-575. doi: 10.1111/jnc.13917.
203 Retigabine ameliorates acute stress-induced impairment of spatial memory retrieval through regulating USP2 signaling pathways in hippocampal CA1 area.Neuropharmacology. 2018 Jun;135:151-162. doi: 10.1016/j.neuropharm.2018.02.034. Epub 2018 Mar 1.
204 Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.Front Pharmacol. 2017 Jun 21;8:399. doi: 10.3389/fphar.2017.00399. eCollection 2017.
205 Reduced CaM Kinase II and CaM Kinase IV Activities Underlie Cognitive Deficits in NCKX2 Heterozygous Mice.Mol Neurobiol. 2018 May;55(5):3889-3900. doi: 10.1007/s12035-017-0596-1. Epub 2017 May 25.
206 Phenotypically distinct subtypes of psychosis accompany novel or rare variants in four different signaling genes.EBioMedicine. 2016 Apr;6:206-214. doi: 10.1016/j.ebiom.2016.03.008. Epub 2016 Mar 8.
207 Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.Arch Neurol. 2008 Apr;65(4):550-3. doi: 10.1001/archneur.65.4.550.
208 Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review.Mayo Clin Proc. 2018 Jan;93(1):68-82. doi: 10.1016/j.mayocp.2017.11.005.
209 CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy.Hum Mol Genet. 2012 Jan 15;21(2):251-67. doi: 10.1093/hmg/ddr492. Epub 2011 Oct 25.
210 DHA Selectively Protects SAMP-8-Associated Cognitive Deficits Through Inhibition of JNK.Mol Neurobiol. 2019 Mar;56(3):1618-1627. doi: 10.1007/s12035-018-1185-7. Epub 2018 Jun 17.
211 The effects of cerebellar damage on maze learning in animals.Cerebellum. 2003;2(4):300-9. doi: 10.1080/14734220310017456.
212 Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice.Neuron. 2002 Feb 28;33(5):789-804. doi: 10.1016/s0896-6273(02)00601-3.
213 Recurrent microdeletions of 15q25.2 are associated with increased risk of congenital diaphragmatic hernia, cognitive deficits and possibly Diamond--Blackfan anaemia.J Med Genet. 2010 Nov;47(11):777-81. doi: 10.1136/jmg.2009.075903. Epub 2010 Oct 4.
214 P50 inhibition deficit in patients with chronic schizophrenia: Relationship with cognitive impairment of MATRICS consensus cognitive battery.Schizophr Res. 2020 Jan;215:105-112. doi: 10.1016/j.schres.2019.11.012. Epub 2019 Nov 25.
215 Suppressed Calbindin Levels in Hippocampal Excitatory Neurons Mediate Stress-Induced Memory Loss.Cell Rep. 2017 Oct 24;21(4):891-900. doi: 10.1016/j.celrep.2017.10.006.
216 Sublaminar organization of the human subplate: developmental changes in the distribution of neurons, glia, growing axons and extracellular matrix.J Anat. 2019 Sep;235(3):481-506. doi: 10.1111/joa.12920. Epub 2018 Dec 13.
217 CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid.Neurosci Lett. 2010 Jan 22;469(2):265-7. doi: 10.1016/j.neulet.2009.12.011. Epub 2009 Dec 23.
218 CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior.Hum Mol Genet. 2003 Jul 1;12(13):1463-74. doi: 10.1093/hmg/ddg165.
219 Williams-Beuren syndrome: a model of recurrent genomic mutation.Horm Res. 2003;59 Suppl 1:106-13. doi: 10.1159/000067836.
220 A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.PLoS One. 2014 Aug 25;9(8):e102136. doi: 10.1371/journal.pone.0102136. eCollection 2014.
221 Interstitial 1p32.1p32.3 deletion in a patient with multiple congenital anomalies.Am J Med Genet A. 2015 Oct;167A(10):2406-10. doi: 10.1002/ajmg.a.37178. Epub 2015 Jun 10.
222 Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration.J Alzheimers Dis. 2017;55(1):73-75. doi: 10.3233/JAD-160878.
223 Disrupted-in-schizophrenia-1 protects synaptic plasticity in a transgenic mouse model of Alzheimer's disease as a mitophagy receptor.Aging Cell. 2019 Feb;18(1):e12860. doi: 10.1111/acel.12860. Epub 2018 Nov 28.
224 Reelin signaling is impaired in autism.Biol Psychiatry. 2005 Apr 1;57(7):777-87. doi: 10.1016/j.biopsych.2004.12.018.
225 Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule.Science. 2018 Mar 30;359(6383):eaaq0939. doi: 10.1126/science.aaq0939.
226 Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders.Annu Rev Med. 2019 Jan 27;70:167-181. doi: 10.1146/annurev-med-081117-041238. Epub 2018 Oct 26.
227 An atypical 7q11.23 deletion in a normal IQ Williams-Beuren syndrome patient.Eur J Hum Genet. 2010 Jan;18(1):33-8. doi: 10.1038/ejhg.2009.108.
228 Seipin deletion in mice enhances phosphorylation and aggregation of tau protein through reduced neuronal PPAR and insulin resistance.Neurobiol Dis. 2019 Jul;127:350-361. doi: 10.1016/j.nbd.2019.03.023. Epub 2019 Mar 22.
229 Two pedigrees segregating Duane's retraction syndrome as a dominant trait map to the DURS2 genetic locus.Invest Ophthalmol Vis Sci. 2007 Jan;48(1):189-93. doi: 10.1167/iovs.06-0631.
230 Global brain atrophy and metabolic dysfunction in LGI1 encephalitis: A prospective multimodal MRI study.J Neurol Sci. 2017 May 15;376:159-165. doi: 10.1016/j.jns.2017.03.020. Epub 2017 Mar 16.
231 Behavioral and cerebellar transmission deficits in mice lacking the autism-linked gene islet brain-2.J Neurosci. 2010 Nov 3;30(44):14805-16. doi: 10.1523/JNEUROSCI.1161-10.2010.
232 The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia.Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13254-9. doi: 10.1073/pnas.95.22.13254.
233 Downregulation of Npas4 in parvalbumin interneurons and cognitive deficits after neonatal NMDA receptor blockade: relevance for schizophrenia.Transl Psychiatry. 2019 Feb 21;9(1):99. doi: 10.1038/s41398-019-0436-3.
234 NRG3 contributes to cognitive deficits in chronic patients with schizophrenia.Schizophr Res. 2020 Jan;215:134-139. doi: 10.1016/j.schres.2019.10.060. Epub 2019 Nov 18.
235 Pioglitazone abolishes cognition impairments as well as BDNF and neurotensin disturbances in a rat model of autism.Biol Open. 2019 May 13;8(5):bio041327. doi: 10.1242/bio.041327.
236 The mental retardation protein PAK3 contributes to synapse formation and plasticity in hippocampus.J Neurosci. 2004 Dec 1;24(48):10816-25. doi: 10.1523/JNEUROSCI.2931-04.2004.
237 Bee venom phospholipase A2 ameliorates Alzheimer's disease pathology in A vaccination treatment without inducing neuro-inflammation in a 3xTg-AD mouse model.Sci Rep. 2018 Nov 26;8(1):17369. doi: 10.1038/s41598-018-35030-1.
238 Chronic Metabolic Derangement-Induced Cognitive Deficits and Neurotoxicity Are Associated with REST Inactivation.Mol Neurobiol. 2019 Mar;56(3):1539-1557. doi: 10.1007/s12035-018-1175-9. Epub 2018 Jun 14.
239 Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis.Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11965-70. doi: 10.1073/pnas.1510011112. Epub 2015 Sep 8.
240 Aberrant topographical organization in default-mode network in first-episode remitted geriatric depression: a graph-theoretical analysis.Int Psychogeriatr. 2018 May;30(5):619-628. doi: 10.1017/S1041610218000054. Epub 2018 Feb 12.
241 Stimulation of ACE2/ANG(1-7)/Mas Axis by Diminazene Ameliorates Alzheimer's Disease in the D-Galactose-Ovariectomized Rat Model: Role of PI3K/Akt Pathway.Mol Neurobiol. 2018 Oct;55(10):8188-8202. doi: 10.1007/s12035-018-0966-3. Epub 2018 Mar 7.
242 Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.NeuroRx. 2006 Jan;3(1):106-16. doi: 10.1016/j.nurx.2005.12.004.
243 D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.J Mol Neurosci. 2012 Nov;48(3):597-602. doi: 10.1007/s12031-012-9882-6.
244 RAB GTPases and RAB-interacting proteins and their role in the control of cognitive functions.Neurosci Biobehav Rev. 2014 Oct;46 Pt 2:302-14. doi: 10.1016/j.neubiorev.2013.12.009. Epub 2014 Jan 9.
245 Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence.Retrovirology. 2013 Jun 8;10:61. doi: 10.1186/1742-4690-10-61.
246 Characterization of the deleted in autism 1 protein family: implications for studying cognitive disorders.PLoS One. 2011 Jan 19;6(1):e14547. doi: 10.1371/journal.pone.0014547.
247 Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing.J Med Genet. 2014 Nov;51(11):724-36. doi: 10.1136/jmedgenet-2014-102554. Epub 2014 Aug 28.
248 Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians.Int J Biol Markers. 2012 Jan-Mar;27(1):34-8. doi: 10.5301/JBM.2011.8830.
249 A homozygous splice site mutation in TRAPPC9 causes intellectual disability and microcephaly.Eur J Med Genet. 2012 Dec;55(12):727-31. doi: 10.1016/j.ejmg.2012.08.010. Epub 2012 Aug 30.
250 Germline gain-of-function mutations in AFF4 cause a developmental syndrome functionally linking the super elongation complex and cohesin. Nat Genet. 2015 Apr;47(4):338-44. doi: 10.1038/ng.3229. Epub 2015 Mar 2.
251 Homozygous and heterozygous disruptions of ANK3: at the crossroads of neurodevelopmental and psychiatric disorders. Hum Mol Genet. 2013 May 15;22(10):1960-70. doi: 10.1093/hmg/ddt043. Epub 2013 Feb 5.
252 ASL Metabolically Regulates Tyrosine Hydroxylase in the Nucleus Locus Coeruleus.Cell Rep. 2019 Nov 19;29(8):2144-2153.e7. doi: 10.1016/j.celrep.2019.10.043.
253 IRSp53/BAIAP2 in dendritic spine development, NMDA receptor regulation, and psychiatric disorders.Neuropharmacology. 2016 Jan;100:27-39. doi: 10.1016/j.neuropharm.2015.06.019. Epub 2015 Aug 12.
254 Conditional Deletion of CC2D1A Reduces Hippocampal Synaptic Plasticity and Impairs Cognitive Function through Rac1 Hyperactivation.J Neurosci. 2019 Jun 19;39(25):4959-4975. doi: 10.1523/JNEUROSCI.2395-18.2019. Epub 2019 Apr 16.
255 CAMDI interacts with the human memory-associated protein KIBRA and regulates AMPAR cell surface expression and cognition.PLoS One. 2019 Nov 15;14(11):e0224967. doi: 10.1371/journal.pone.0224967. eCollection 2019.
256 Nicotine versus 6-hydroxy-l-nicotine against chlorisondamine induced memory impairment and oxidative stress in the rat hippocampus.Biomed Pharmacother. 2017 Feb;86:102-108. doi: 10.1016/j.biopha.2016.12.008. Epub 2016 Dec 9.
257 CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits.Neurobiol Aging. 2019 Mar;75:198-208. doi: 10.1016/j.neurobiolaging.2018.11.023. Epub 2018 Dec 6.
258 DEGS2 polymorphism associated with cognition in schizophrenia is associated with gene expression in brain.Transl Psychiatry. 2015 Apr 14;5(4):e550. doi: 10.1038/tp.2015.45.
259 Loss of dysbindin-1 affects GABAergic transmission in the PFC.Psychopharmacology (Berl). 2019 Nov;236(11):3291-3300. doi: 10.1007/s00213-019-05285-1. Epub 2019 Jun 14.
260 Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.Hum Mol Genet. 2002 May 15;11(11):1263-71. doi: 10.1093/hmg/11.11.1263.
261 Loss of Frrs1l disrupts synaptic AMPA receptor function, and results in neurodevelopmental, motor, cognitive and electrographical abnormalities.Dis Model Mech. 2019 Feb 22;12(2):dmm036806. doi: 10.1242/dmm.036806.
262 Mimicking Age-Associated Gadd45 Dysregulation Results in Memory Impairments in Young Adult Mice.J Neurosci. 2020 Feb 5;40(6):1197-1210. doi: 10.1523/JNEUROSCI.1621-19.2019. Epub 2019 Dec 11.
263 Maternal choline supplementation ameliorates Alzheimer's disease pathology by reducing brain homocysteine levels across multiple generations.Mol Psychiatry. 2020 Oct;25(10):2620-2629. doi: 10.1038/s41380-018-0322-z. Epub 2019 Jan 8.
264 Epigenetics and memory: Emerging role of histone lysine methyltransferase G9a/GLP complex as bidirectional regulator of synaptic plasticity.Neurobiol Learn Mem. 2019 Mar;159:1-5. doi: 10.1016/j.nlm.2019.01.013. Epub 2019 Jan 28.
265 Peripheral neuropathy and cognitive impairment associated with a novel monoallelic HARS variant.Ann Clin Transl Neurol. 2019 May 24;6(6):1072-1080. doi: 10.1002/acn3.791. eCollection 2019 Jun.
266 Lentiviral vector-mediated overexpression of Klotho in the brain improves Alzheimer's disease-like pathology and cognitive deficits in mice.Neurobiol Aging. 2019 Jun;78:18-28. doi: 10.1016/j.neurobiolaging.2019.02.003. Epub 2019 Feb 13.
267 SFRS11 Loss Leads to Aging-Associated Cognitive Decline by Modulating LRP8 and ApoE.Cell Rep. 2019 Jul 2;28(1):78-90.e6. doi: 10.1016/j.celrep.2019.06.002.
268 Lynx1 Prevents Long-Term Potentiation Blockade and Reduction of Neuromodulator Expression Caused by A1-42 and JNK Activation.Acta Naturae. 2018 Jul-Sep;10(3):57-61.
269 Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.Cell Rep. 2018 Aug 7;24(6):1523-1535. doi: 10.1016/j.celrep.2018.07.006.
270 Mice lacking neuronal calcium sensor-1 show social and cognitive deficits.Behav Brain Res. 2020 Mar 2;381:112420. doi: 10.1016/j.bbr.2019.112420. Epub 2019 Dec 9.
271 Neuropeptide S Ameliorates Cognitive Impairment of APP/PS1 Transgenic Mice by Promoting Synaptic Plasticity and Reducing A Deposition.Front Behav Neurosci. 2019 Jun 25;13:138. doi: 10.3389/fnbeh.2019.00138. eCollection 2019.
272 Neurogranin Expression Is Regulated by Synaptic Activity and Promotes Synaptogenesis in Cultured Hippocampal Neurons.Mol Neurobiol. 2019 Nov;56(11):7321-7337. doi: 10.1007/s12035-019-1593-3. Epub 2019 Apr 24.
273 Cognitive deficits in mice lacking Nsun5, a cytosine-5 RNA methyltransferase, with impairment of oligodendrocyte precursor cells.Glia. 2019 Apr;67(4):688-702. doi: 10.1002/glia.23565. Epub 2018 Nov 28.
274 Myelin Deficits Caused by Olig2 Deficiency Lead to Cognitive Dysfunction and Increase Vulnerability to Social Withdrawal in Adult Mice.Neurosci Bull. 2020 Apr;36(4):419-426. doi: 10.1007/s12264-019-00449-7. Epub 2019 Nov 22.
275 Autism spectrum disorder phenotype and intellectual disability in females with epilepsy and PCDH-19 mutations.Epilepsy Behav. 2016 Jul;60:75-80. doi: 10.1016/j.yebeh.2016.04.009. Epub 2016 May 12.
276 Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia.Schizophr Res. 2019 Jul;209:135-140. doi: 10.1016/j.schres.2019.05.006. Epub 2019 May 14.
277 Tau inhibits PKA by nuclear proteasome-dependent PKAR2 elevation with suppressed CREB/GluA1 phosphorylation.Aging Cell. 2020 Jan;19(1):e13055. doi: 10.1111/acel.13055. Epub 2019 Oct 31.
278 Hypervulnerability of the adolescent prefrontal cortex to nutritional stress via reelin deficiency.Mol Psychiatry. 2017 Jul;22(7):961-971. doi: 10.1038/mp.2016.193. Epub 2016 Nov 15.
279 Recapitulation and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice.Neuron. 2019 Nov 6;104(3):471-487.e12. doi: 10.1016/j.neuron.2019.09.014. Epub 2019 Oct 9.
280 Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0.
281 Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse.J Neurosci. 2016 Aug 17;36(33):8653-67. doi: 10.1523/JNEUROSCI.1429-16.2016.
282 Synaptic Interactome Mining Reveals p140Cap as a New Hub for PSD Proteins Involved in Psychiatric and Neurological Disorders.Front Mol Neurosci. 2017 Jun 30;10:212. doi: 10.3389/fnmol.2017.00212. eCollection 2017.
283 Santacruzamate A Ameliorates AD-Like Pathology by Enhancing ER Stress Tolerance Through Regulating the Functions of KDELR and Mia40-ALR in vivo and in vitro.Front Cell Neurosci. 2019 Mar 4;13:61. doi: 10.3389/fncel.2019.00061. eCollection 2019.
284 Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes.Cell Syst. 2017 Apr 26;4(4):404-415.e5. doi: 10.1016/j.cels.2017.02.009. Epub 2017 Mar 18.
285 Overexpression of TIPE2, a Negative Regulator of Innate and Adaptive Immunity, Attenuates Cognitive Deficits in APP/PS1 Mice.J Neuroimmune Pharmacol. 2019 Sep;14(3):519-529. doi: 10.1007/s11481-019-09861-2. Epub 2019 Jul 8.
286 A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer's Disease in 5XFAD Mice.J Alzheimers Dis. 2017;58(2):389-400. doi: 10.3233/JAD-161236.
287 Knockdown of pp32 Increases Histone Acetylation and Ameliorates Cognitive Deficits.Front Aging Neurosci. 2017 Apr 20;9:104. doi: 10.3389/fnagi.2017.00104. eCollection 2017.
288 Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia.Mol Neurobiol. 2017 Apr;54(3):1699-1709. doi: 10.1007/s12035-016-9773-x. Epub 2016 Feb 12.
289 Do cognitive deficits persist into adolescence in autism?.Autism Res. 2018 Sep;11(9):1229-1238. doi: 10.1002/aur.1976. Epub 2018 Sep 28.
290 Polymorphisms within ASTN2 gene are associated with age at onset of Alzheimer's disease.J Neural Transm (Vienna). 2015 May;122(5):701-8. doi: 10.1007/s00702-014-1306-z. Epub 2014 Nov 21.
291 Cognitive deficits caused by a disease-mutation in the 3 Na(+)/K(+)-ATPase isoform.Sci Rep. 2016 Aug 23;6:31972. doi: 10.1038/srep31972.
292 The 2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat.Behav Pharmacol. 2017 Feb;28(1):9-18. doi: 10.1097/FBP.0000000000000261.
293 Cocaine-Induced Chromatin Modifications Associate With Increased Expression and Three-Dimensional Looping of Auts2.Biol Psychiatry. 2017 Dec 1;82(11):794-805. doi: 10.1016/j.biopsych.2017.04.013. Epub 2017 May 5.
294 Differences Between Women With Traumatic and Idiopathic Chronic Neck Pain and Women Without Neck Pain: Interrelationships Among Disability, Cognitive Deficits, and Central Sensitization.Phys Ther. 2017 Mar 1;97(3):338-353. doi: 10.2522/ptj.20160259.
295 Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice.Transl Psychiatry. 2018 Mar 1;8(1):53. doi: 10.1038/s41398-018-0101-2.
296 From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline.J Psychiatr Res. 2018 Jan;96:231-238. doi: 10.1016/j.jpsychires.2017.10.014. Epub 2017 Oct 19.
297 Temporal profiling of an acute stress-induced behavioral phenotype in mice and role of hippocampal DRR1.Psychoneuroendocrinology. 2018 May;91:149-158. doi: 10.1016/j.psyneuen.2018.03.004. Epub 2018 Mar 8.
298 FosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes.Neuropsychopharmacology. 2014 Feb;39(3):538-44. doi: 10.1038/npp.2013.255. Epub 2013 Sep 26.
299 Use of neuropsychological tests for the diagnosis of dementia: a survey of Italian memory clinics.BMJ Open. 2018 Mar 28;8(3):e017847. doi: 10.1136/bmjopen-2017-017847.
300 Risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances Notch signaling in a murine model of schizophrenia.Pharmacol Biochem Behav. 2017 Dec;163:101-109. doi: 10.1016/j.pbb.2017.09.010. Epub 2017 Oct 14.
301 Disruption of AT-hook 1 domain in MeCP2 protein caused behavioral abnormality in mice.Biochim Biophys Acta Mol Basis Dis. 2018 Feb;1864(2):347-358. doi: 10.1016/j.bbadis.2017.10.022. Epub 2017 Oct 24.
302 Exercise Rehabilitation Attenuates Cognitive Deficits in Rats with Traumatic Brain Injury by Stimulating the Cerebral HSP20/BDNF/TrkB Signalling Axis.Mol Neurobiol. 2018 Nov;55(11):8602-8611. doi: 10.1007/s12035-018-1011-2. Epub 2018 Mar 25.
303 The X-Linked Intellectual Disability Protein IL1RAPL1 Regulates Dendrite Complexity.J Neurosci. 2017 Jul 12;37(28):6606-6627. doi: 10.1523/JNEUROSCI.3775-16.2017. Epub 2017 Jun 2.
304 Suppressing Irf2bp2 expressions accelerates metabolic syndrome-associated brain injury and hepatic dyslipidemia.Biochem Biophys Res Commun. 2018 Sep 10;503(3):1651-1658. doi: 10.1016/j.bbrc.2018.07.095. Epub 2018 Aug 18.
305 Residential Proximity to Major Roadways at Birth, DNA Methylation at Birth and Midchildhood, and Childhood Cognitive Test Scores: Project Viva(Massachusetts, USA).Environ Health Perspect. 2018 Sep;126(9):97006. doi: 10.1289/EHP2034.
306 Neuropsychological correlates of instrumental activities of daily living in neurocognitive disorders: a possible role for executive dysfunction and mood changes.Int Psychogeriatr. 2018 Dec;30(12):1871-1881. doi: 10.1017/S1041610218000455. Epub 2018 May 23.
307 Orchiectomy and letrozole differentially regulate synaptic plasticity and spatial memory in a manner that is mediated by SRC-1 in the hippocampus of male mice.J Steroid Biochem Mol Biol. 2018 Apr;178:354-368. doi: 10.1016/j.jsbmb.2018.02.007. Epub 2018 Feb 13.
308 Nectin-3 modulates the structural plasticity of dentate granule cells and long-term memory.Transl Psychiatry. 2017 Sep 5;7(9):e1228. doi: 10.1038/tp.2017.196.
309 The Intellectual Disability and Schizophrenia Associated Transcription Factor TCF4 Is Regulated by Neuronal Activity and Protein Kinase A.J Neurosci. 2017 Oct 25;37(43):10516-10527. doi: 10.1523/JNEUROSCI.1151-17.2017. Epub 2017 Sep 26.
310 Cognitive Deficits Are Attenuated in Neuroglobin Overexpressing Mice Exposed to a Model of Obstructive Sleep Apnea.Front Neurol. 2018 Jun 5;9:426. doi: 10.3389/fneur.2018.00426. eCollection 2018.
311 Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease.Neurobiol Dis. 2018 Dec;120:88-97. doi: 10.1016/j.nbd.2018.08.024. Epub 2018 Aug 31.
312 Disruption of RAB40AL function leads to Martin--Probst syndrome, a rare X-linked multisystem neurodevelopmental human disorder.J Med Genet. 2012 May;49(5):332-40. doi: 10.1136/jmedgenet-2011-100575.
313 RTN3 Is a Novel Cold-Induced Protein and Mediates Neuroprotective Effects of RBM3.Curr Biol. 2017 Mar 6;27(5):638-650. doi: 10.1016/j.cub.2017.01.047. Epub 2017 Feb 23.
314 Epilepsy and intellectual disability linked protein Shrm4 interaction with GABA(B)Rs shapes inhibitory neurotransmission.Nat Commun. 2017 Mar 6;8:14536. doi: 10.1038/ncomms14536.
315 Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet. 2011 Dec 11;44(1):85-8. doi: 10.1038/ng.1016.
316 Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration.Neurobiol Dis. 2017 Jun;102:21-37. doi: 10.1016/j.nbd.2017.02.007. Epub 2017 Feb 22.
317 Decrease of SYNGAP1 in GABAergic cells impairs inhibitory synapse connectivity, synaptic inhibition and cognitive function.Nat Commun. 2016 Nov 9;7:13340. doi: 10.1038/ncomms13340.
318 Protective effect of S-nitrosoglutathione administration against hyperglycemia induced disruption of blood brain barrier is mediated by modulation of tight junction proteins and cell adhesion molecules.Neurochem Int. 2018 Sep;118:205-216. doi: 10.1016/j.neuint.2018.05.009. Epub 2018 May 21.
319 RAGE and AGEs in Mild Cognitive Impairment of Diabetic Patients: A Cross-Sectional Study.PLoS One. 2016 Jan 8;11(1):e0145521. doi: 10.1371/journal.pone.0145521. eCollection 2016.
320 Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures.Ann Neurol. 2007 Dec;62(6):648-55. doi: 10.1002/ana.21317.